Genascence is pioneering advancements in gene therapy specifically targeting musculoskeletal diseases, with a focus on osteoarthritis (OA), a leading cause of disability and chronic pain. The company utilizes a genetic medicine approach, developing a recombinant adeno-associated virus vector known as GNSC-001. This vector carries the coding sequence for interleukin-1 receptor antagonist (IL-1Ra), which is designed to inhibit the inflammatory effects of interleukin 1 (IL-1), a key molecule involved in the progression of OA. By administering GNSC-001 through a one-time intra-articular injection, the therapy aims to provide long-term relief from symptoms and improve joint structure, as demonstrated in pre-clinical studies.

Genascence's innovative strategy involves transforming synovial cells and chondrocytes into biofactories that produce IL-1Ra, effectively blocking the pathological signaling of IL-1. This approach not only addresses the inflammation and cartilage destruction associated with OA but also holds the potential to revolutionize treatment for millions affected by this condition. The company is committed to rigorous clinical trials to ensure the safety and efficacy of GNSC-001, adhering to the regulatory standards set by the U.S. Food and Drug Administration. Through these efforts, Genascence aims to make significant strides in the development of life-changing therapies for prevalent musculoskeletal disorders.

United States

A Biotechnology Research private company. Mission is to take on one of the largest problems in all of medicine – the leading cause of disability, chronic pain, and a significant risk factor for opioid addiction – osteoarthritis (OA).

Genascence

Company Details